
    
      This was a three-centre, double-blind, randomised, placebo-controlled, crossover study with
      four consecutive single-dose treatment periods in PD patients treated with immediate release
      100 mg/25 mg levodopa/carbidopa or 100 mg/25 mg levodopa/benserazide
    
  